What is Leinco Technologies?
Founded in 1992, Leinco Technologies, Inc. operates as a specialized biotechnology firm. The company initially focused on manufacturing early discovery research products, including antibodies, recombinant proteins, and ELISA kits. Over time, Leinco Technologies expanded its offerings to become a premier provider of custom research and development and manufacturing services, with a particular emphasis on monoclonal antibodies and recombinant proteins. These innovative products and services are instrumental in advancing the early stages of life science research, diagnostics, and the development of protein therapeutics.
How much funding has Leinco Technologies raised?
Leinco Technologies has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Leinco Technologies
PPP
Public-Private Partnership
What's next for Leinco Technologies?
The company's large-scale late-stage funding context suggests a strategic phase of scaling operations, expanding market reach, or investing in further research and development to solidify its position in the competitive biotechnology landscape. The recent strategic investment indicates a strong vote of confidence from its backers, likely positioning Leinco Technologies for accelerated growth and innovation in the development of novel life science products and therapeutic solutions.
See full Leinco Technologies company page
